Dipòsit Digital de Documents de la UAB 16 registres trobats  1 - 10següent  anar al registre: La cerca s'ha fet en 0.01 segons. 
1.
8 p, 732.8 KB Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation / Gagelmann, N. (University Medical Center Hamburg-Eppendorf) ; Eikema, D.J. (EBMT Statistics) ; Stelljes, M. (University of Münster) ; Beelen, D. (University Hospital of Essen) ; de Wreede, L. (EBMT Statistics) ; Mufti, G. (GKT School of Medicine) ; Knelange, N.S. (EBMT Data Office) ; Niederwieser, D. (University Hospital Leipzig) ; Friis, L.S. (University of Copenhagen) ; Ehninger, G. (Universitätsklinikum Dresden) ; Nagler, A. (Chaim Sheba Medical Center (Israel)) ; Yakoub-Agha, I. (Université Lille2) ; Meijer, E. (Amsterdam UMC. University Medical Center) ; Ljungman, P. (Karolinska University Hospital and Karolinska Institutet) ; Maertens, J. (University Hospital Gasthuisberg) ; Kanz, L. (Universität Tübingen) ; Lopez-Corral, L. (Hospital Clínico (Salamanca)) ; Brecht, A. (Deutsche Klinik für Diagnostik) ; Craddock, C. (Centre for Clinical Haematology) ; Finke, J. (University of Freiburg) ; Cornelissen, J.J. (Erasmus MC Cancer Institute. Erasmus University Medical Center) ; Bernasconi, P. (Fondazione IRCCS Policlinico San Matteo) ; Chevallier, P. (CHU Nantes) ; Sierra, Jorge (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Robin, M. (Hopital St. Louis) ; Kröger, N. (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. [...]
2019 - 10.3324/haematol.2018.200808
Haematologica, Vol. 104 Núm. 5 (30 2019) , p. 929-936  
2.
13 p, 4.7 MB Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis / Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Rogers, R.B. (Department of Medicine. University of Cambridge. Cambridge Biomedical Campus) ; Roy, A. (Department of Paediatrics. University of Oxford) ; Schneider, P. (Princess Maxima Center for Pediatric Oncology) ; Bardini, M. (Centro Ricerca Tettamanti. Department of Pediatrics. University of Milano Bicocca. Fondazione MBBM) ; Ballerini, P. (Pediatric Hematology. A. Trousseau Hospital) ; Cazzaniga, G. (Centro Ricerca Tettamanti. Department of Pediatrics. University of Milano Bicocca. Fondazione MBBM) ; Moreno, T. (Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC). Universidad de Cantabria-CSIC) ; Revilla, C. (Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC). Universidad de Cantabria-CSIC) ; Gut, M. (Universitat Pompeu Fabra) ; Valsecchi, M.G. (Interfant Trial Data Center. University of Milano-Bicocca) ; Roberts, I. (MRC Molecular Haematology Unit. MRC Weatherall Institute of Molecular Medicine. University of Oxford) ; Pieters, R. (Princess Maxima Center for Pediatric Oncology) ; De Lorenzo, P. (Interfant Trial Data Center. University of Milano-Bicocca) ; Varela, I. (Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC). Universidad de Cantabria-CSIC) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Stam, R.W. (Princess Maxima Center for Pediatric Oncology) ; Universitat Autònoma de Barcelona
Bcell acute lymphoblastic leukemia is the commonest childhood cancer. In infants, B-cell acute lymphoblastic leukemia remains fatal, especially in patients with t(4;11), present in ~80% of cases. The pathogenesis of t(4;11)/KMT2A-AFF1 (MLL-AF4) infant B-cell acute lymphoblastic leukemia remains difficult to model, and the pathogenic contribution in cancer of the reciprocal fusions resulting from derivative translocated-chromosomes remains obscure. [...]
2019 - 10.3324/haematol.2018.206375
Haematologica, Vol. 104 Núm. 6 (2019) , p. 1176-1188  
3.
13 p, 3.9 MB Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions / Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Calero-Nieto, F.J. (Department of Hematology. Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. University of Cambridge) ; Wang, X. (Department of Hematology. Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. University of Cambridge) ; Valdes-Mas, R. (Dreamgenics S.L. Oviedo) ; Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ayllon, V. (GENyO. Centre for Genomics and Oncological Research. Pfizer/University of Granada/Andalusian Regional Government and University of Granada. Department of Biochemistry and Molecular Biology) ; Real, P.J. (GENyO. Centre for Genomics and Oncological Research. Pfizer/University of Granada/Andalusian Regional Government and University of Granada. Department of Biochemistry and Molecular Biology) ; Arambilet Mobilla, David (Institut Hospital del Mar d'Investigacions Mèdiques) ; Espinosa, Lluís (Institut Hospital del Mar d'Investigacions Mèdiques) ; Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Varela, I. (Instituto de Biomedicina y Biotecnologia de Cantabria (CSIC-UC-Sodercan). Departamento de Biologia Molecular. Universidad de Cantabria) ; De Boer, J. (Cancer Section. UCL Great Ormond Street Institute of Child Health) ; Bigas, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ; Gottgens, B. (Department of Hematology. Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. University of Cambridge) ; Marschalek, R. (Institute of Pharmaceutical Biology. Goethe-University) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed in patients with t(4;11)+ B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is expressed in only half of the patients. [...]
2019 - 10.3324/haematol.2018.202044
Haematologica, Vol. 104 Núm. 6 (2019) , p. 1189-1201  
4.
11 p, 1.9 MB Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma / Recasens-Zorzo, C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cardesa-Salzmann, T. (Hospital Clínic i Provincial de Barcelona) ; Petazzi, Paolo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ros-Blanco, L. (Universitat Ramon Llull. IQS School of Engineering) ; Esteve-Arenys, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Clot, G. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Guerrero-Hernández, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Rodríguez, V. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Soldini, D. (Hospital Clínic i Provincial de Barcelona) ; Valera, A. (Hospital Clínic i Provincial de Barcelona) ; Moros, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Climent, F. (Hospital Universitari de Bellvitge) ; González-Barca, E. (Institut Català d'Oncologia) ; Mercadal, Santiago (Institut Català d'Oncologia) ; Arenillas, Leonor (Institut Hospital del Mar d'Investigacions Mèdiques) ; Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Mate, J.L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gutiérrez-García, G. (Hospital Clínic i Provincial de Barcelona) ; Casanova Rigat, Isolda (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mangues, Ramon (Institut d'Investigació Biomèdica Sant Pau) ; Sanjuan-Pla, A. (Hospital Universitari i Politècnic La Fe (València)) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez, A. (Hospital Clínic i Provincial de Barcelona) ; Colomer, D. (Hospital Clínic i Provincial de Barcelona) ; Tejedor, R.E. (Universitat Ramon Llull) ; Teixidó, J. (Universitat Ramon Llull) ; Campo, E. (Hospital Clínic i Provincial de Barcelona) ; López-Guillermo, A. (Hospital Clínic i Provincial de Barcelona) ; Borrell, J.I. (Universitat Ramon Llull) ; Colomo, Luís (Institut Hospital del Mar d'Investigacions Mèdiques) ; Pérez-Galán, P. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Roué, Gaël (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Constitutive activation of the chemokine receptor CXCR4 has been associated with tumor progression, invasion, and chemotherapy resistance in different cancer subtypes. Although the CXCR4 pathway has recently been suggested as an adverse prognostic marker in diffuse large B-cell lymphoma, its biological relevance in this disease remains underexplored. [...]
2019 - 10.3324/haematol.2017.180505
Haematologica, Vol. 104 Núm. 4 (31 2019) , p. 778-788  
5.
9 p, 6.7 MB Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas / Bobillo, Sabela (Vall d'Hebron Institut d'Oncologia) ; Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ; Escudero, Laura (Vall d'Hebron Institut d'Oncologia) ; Mayor, Regina (Hospital Universitari Vall d'Hebron) ; Raheja, Priyanka (Vall d'Hebron Institut d'Oncologia) ; Carpio, Cecilia (Vall d'Hebron Institut d'Oncologia) ; Rubio-Perez, Carlota (Vall d'Hebron Institut d'Oncologia) ; Tazon-Vega, Barbara ; Palacio, Carlos (Vall d'Hebron Institut d'Oncologia) ; Carabia, Julia (Vall d'Hebron Institut d'Oncologia) ; Jimenez, Isabel (Vall d'Hebron Institut d'Oncologia) ; Nieto, Juan. C. (Vall d'Hebron Institut d'Oncologia) ; Montoro, Julia (Vall d'Hebron Institut d'Oncologia) ; Martinez-Ricarte, Francisco (Hospital Universitari Vall d'Hebron) ; Castellvi, Josep (Hospital Universitari Vall d'Hebron) ; Simo, Marc (Hospital Universitari Vall d'Hebron) ; Puigdefabregas, Lluis (Vall d'Hebron Institut d'Oncologia) ; Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ; Bosch, Francesc (Vall d'Hebron Institut d'Oncologia) ; Seoane, Joan (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
The levels of cell free circulating tumor DNA (ctDNA) in plasma correlate with treatment response and outcome in systemic lymphomas. Notably, in brain tumors, the levels of ctDNA in the cerebrospinal fluid (CSF) are higher than in plasma. [...]
2020 - 10.3324/haematol.2019.241208
Haematologica, Vol. 106 (february 2020) , p. 513-521  
6.
12 p, 4.6 MB Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma / Perez-Amill, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Suñe, G. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Antoñana-Vildosola, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Castella, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Najjar, A. (Department of Pediatrics - Research. The University of Texas M. D. Anderson Cancer Center) ; Bonet, J. (Laboratory of Protein Design and Immunoengineering. École Polytechnique Fédérale de Lausanne) ; Fernández-Fuentes, N. (Universitat de Vic - Universitat Central de Catalunya) ; Inogés, S. (Clínica Universidad de Navarra) ; López, A. (Clínica Universidad de Navarra) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Juan, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martín-Antonio, B. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective drugs. The recent development of chimeric antigen receptor (CAR)T cells has shown impressive results in the treatment of patients with relapsed or refractory hematologic B-cell malignancies. [...]
2021 - 10.3324/haematol.2019.228577
Haematologica, Vol. 106 Núm. 1 (january 2021) , p. 173-184  
7.
4 p, 227.0 KB Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia / Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Montesinos, P. (Hospital Universitari i Politècnic La Fe (València)) ; Barba, Pere (Hospital Universitari Vall d'Hebron) ; Gil, C. (Clinical Hematology Service. Hospital General de Alicante) ; Guàrdia, R. (Hospital Universitari de Girona Doctor Josep Trueta) ; Moreno, M.J. (Clinical Hematology Service. Hospital Vírgen de la Victoria) ; Martínez-Carballeira, D. (Clinical Hematology Service. Hospital Universitario Central de Asturias) ; García Cadenas, Irene. (Institut d'Investigació Biomèdica Sant Pau) ; Vives Polo, Susana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ribera Salas, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; González-Campos, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; González Gil, Celia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramírez, J.L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Díaz-Beya, M. (Hospital Clínic i Provincial de Barcelona) ; Mercadal, Santiago (Clinical Hematology Service. Hospital Duran i Reynals-ICO. Hospitalet del Llobregat) ; Artola, M.T. (Clinical Hematology Service. Hospital Universitario de Donostia) ; Cladera, A. (Clinical Hematology Service. Hospital Son Llàtzer) ; Tormo, M. (Hospital Clínic Universitari (València)) ; Bermúdez, A. (Clinical Hematology Service. Hospital Marqués de Valdecilla) ; Vall-Llovera, F. (Hospital Universitari MútuaTerrassa) ; Martínez, P. (Hospital Universitario 12 de Octubre (Madrid)) ; Amigo, M.L. (Clinical Hematology Service. Hospital Morales Meseguer) ; Monsalvo, S. (Hospital Gregorio Marañón (Madrid)) ; Novo, A. (Clinical Hematology Service. Hospital Son Espases) ; Cervera, M. (Hospital Universitari Joan XXIII de Tarragona) ; García-Guiñon, A. (Clinical Hematology Service. Hospital Arnau de Vilanova) ; Junca, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ciudad, J. (Centro de Investigación del Cáncer (IBMCC-CSIC/USAL). Hospital Clínico Universitario de Salamanca. Instituto Bio-Sanitario de Salamanca. CIBERONC) ; Orfao, A. (Centro de Investigación del Cáncer (IBMCC-CSIC/USAL). Hospital Clínico Universitario de Salamanca. Instituto Bio-Sanitario de Salamanca. CIBERONC) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2020 - 10.3324/haematol.2019.225078
Haematologica, Vol. 105 Núm. 6 (january 2020) , p. E294-E297  
8.
10 p, 2.4 MB Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens / Vidal-Crespo, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Matas-Céspedes, A. (Centro de Investigación Biomédica en Red de Cáncer) ; Rodriguez, V. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Rossi, C. (Department of Hematology. Dijon University Hospital) ; Valero, J.G. (Centro de Investigación Biomédica en Red de Cáncer) ; Serrat, N. (Centro de Investigación Biomédica en Red de Cáncer) ; Sanjuan-Pla, Alejandra (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Roué, Gaël (Vall d'Hebron Institut d'Oncologia) ; López-Guillermo, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Giné, E. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Campo, E. (Universitat de Barcelona. Facultat de Medicina) ; Colomer, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bezombes, C. (Centre de Recherches en Cancérologie de Toulouse (CRCT). UMR1037 INSERM. Université Toulouse III: Paul-Sabatier. ERL5294 CNRS. Université de Toulouse) ; van Bueren, J.L. (Genmab) ; Chiu, C. (Janssen R&D) ; Doshi, P. (Janssen R&D) ; Pérez-Galán, P. (Centro de Investigación Biomédica en Red de Cáncer) ; Universitat Autònoma de Barcelona
CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). [...]
2020 - 10.3324/haematol.2018.211904
Haematologica, Vol. 105 Núm. 4 (2020) , p. 1032-1041  
9.
10 p, 1.8 MB Density, heterogeneity and deformability of red cells as markers of clinical severity in hereditary spherocytosis / Huisjes, R. (Department of Clinical Chemistry and Hematology. University Medical Center Utrecht. Utrecht University) ; Makhro, A. (Red Blood Cell Research Group. Institute of Veterinary Physiology. Vetsuisse Faculty. Zurich Center for Integrative Human Physiology (ZIHP). University of Zurich) ; Llaudet-Planas, Esther (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hertz, L. (Theoretical Medicine and Biosciences. Medical Faculty. Saarland University) ; Petkova-Kirova, P. (Theoretical Medicine and Biosciences. Medical Faculty. Saarland University) ; Verhagen, L.P. (Department of Clinical Chemistry and Hematology. University Medical Center Utrecht. Utrecht University) ; Pignatelli, S. (Department of Clinical Chemistry and Hematology. University Medical Center Utrecht. Utrecht University) ; Rab, M.A.E. (Department of Clinical Chemistry and Hematology. University Medical Center Utrecht. Utrecht University) ; Schiffelers, R.M. (Department of Clinical Chemistry and Hematology. University Medical Center Utrecht. Utrecht University) ; Seiler, E. (Red Blood Cell Research Group. Institute of Veterinary Physiology. Vetsuisse Faculty. Zurich Center for Integrative Human Physiology (ZIHP). University of Zurich) ; Van Solinge, W.W. (Department of Clinical Chemistry and Hematology. University Medical Center Utrecht. Utrecht University) ; Vives Corrons, Juan Luís (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Kaestner, L. (Experimental Physics. Saarland University) ; Mañu Pereira, Mª del Mar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Bogdanov, A. (Red Blood Cell Research Group. Institute of Veterinary Physiology. Vetsuisse Faculty. Zurich Center for Integrative Human Physiology (ZIHP). University of Zurich) ; Van Wijk, R. (Department of Clinical Chemistry and Hematology. University Medical Center Utrecht. Utrecht University) ; Universitat Autònoma de Barcelona
Hereditary spherocytosis (HS) originates from defective anchoring of the cytoskeletal network to the transmembrane protein complexes of the red blood cell (RBC). Red cells in HS are characterized by membrane instability and reduced deformability and there is marked heterogeneity in disease severity among patients. [...]
2020 - 10.3324/haematol.2018.188151
Haematologica, Vol. 105 Núm. 2 (31 2020) , p. 338-347  
10.
12 p, 2.5 MB Unraveling the effect of silent, intronic and missense mutations on VWF splicing : contribution of next generation sequencing in the study of mRNA / Borràs, Nina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Orriols, Gerard (Institut d'Investigació Biomèdica Sant Pau) ; Batlle, Javier (Complexo Hospitalario Universitario A Coruña, INIBIC, Spain) ; Pérez-Rodríguez, Almudena (Complexo Hospitalario Universitario A Coruña, INIBIC, Spain) ; Fidalgo, Teresa (Centro Hospitalar e Universitário de Coimbra, Portugal) ; Martinho, Patricia (Centro Hospitalar e Universitário de Coimbra, Portugal) ; López-Fernández, María Fernanda (Complexo Hospitalario Universitario A Coruña, INIBIC, Spain) ; Rodríguez-Trillo, Ángela (Complexo Hospitalario Universitario A Coruña, INIBIC, Spain) ; Lourés, Esther (Complexo Hospitalario Universitario A Coruña, INIBIC, Spain) ; Parra, Rafael (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Altisent, Carme (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cid, Ana Rosa (Hospital Universitario y Politécnico La Fe, Valencia, Spain) ; Bonanad, Santiago (Hospital Universitario y Politécnico La Fe, Valencia, Spain) ; Cabrera, Noelia (Hospital Universitario y Politécnico La Fe, Valencia, Spain) ; Moret, Andrés (Hospital Universitario y Politécnico La Fe, Valencia, Spain) ; Mingot-Castellano, María Eva (Hospital Regional Universitario de Málaga, Spain) ; Navarro, Nira (Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain) ; Pérez-Montes, Rocío (Hospital Universitario Marqués de Valdecilla, Santander, Spain) ; Marcellin, Sally (Salud Castilla y León, Segovia, Spain) ; Moreto, Ana (Hospital Universitario Cruces, Barakaldo, Spain) ; Herrero, Sonia (Hospital Universitario de Guadalajara, Spain) ; Soto, Inmaculada (Hospital Universitario Central de Asturias, Oviedo, Spain) ; Fernández-Mosteirín, Núria (Hospital Universitario Miguel Servet, Zaragoza, Spain) ; Jiménez-Yuste, Víctor (Hospital Universitario La Paz (Madrid)) ; Alonso, Nieves (Hospital Infanta Cristina, Badajoz, Spain) ; de Andrés-Jacob, Aurora (Complexo Hospitalario Universitario Santiago de Compostela, Spain) ; Fontanes, Emilia (Hospital Universitario Lucus Augusti (Lugo)) ; Campos, Rosa (Hospital Jerez de la Frontera, Cádiz, Spain) ; Paloma, María José (Hospital Virgen del Camino, Pamplona, Spain) ; Bermejo, Nuria (Hospital San Pedro de Alcántara) ; Berrueco, Ruben (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Mateo, José (Institut d'Investigació Biomèdica Sant Pau) ; Arribalzaga, Karmele (Hospital Universitario Fundación de Alcorcón, Madrid, Spain) ; Marco, Pascual (Hospital General de Alicante, Spain) ; Palomo, Ángeles (Hospital Regional Universitario Carlos Haya, Málaga, Spain) ; Quismondo, Nerea Castro (Hospital Universitario 12 de Octubre (Madrid)) ; Iñigo, Belén (Hospital Clínico San Carlos (Madrid)) ; Nieto, María del Mar (Complejo Hospitalario de Jaén, Spain) ; Vidal, Rosa (Hospital Universitario Fundación Jiménez Díaz) ; Martínez, María Paz (Hospital Nuestra Sra. de Sonsoles de Ávila, Spain) ; Aguinaco, Reyes (Hospital Universitari Joan XXIII de Tarragona) ; Tenorio, Jesús María (Hospital Montecelo de Pontevedra) ; Ferreiro, María (Hospital Montecelo de Pontevedra) ; García-Frade, Javier (Hospital Río Hortega, Valladolid, Spain) ; Rodríguez-Huerta, Ana María (Hospital Gregorio Marañón (Madrid)) ; Cuesta, Jorge (Hospital Virgen de la Salud, Toledo, Spain) ; Rodríguez-González, Ramón (Hospital Severo Ochoa) ; García-Candel, Faustino (Hospital Universitario Virgen Arrixaca, Murcia, Spain) ; Dobón, Manuela (Hospital Lozano Blesa, Zaragoza, Spain) ; Aguilar, Carlos (Hospital Santa Bárbara, Soria, Spain) ; Vidal, Francisco (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Corrales, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Large studies in von Willebrand disease patients, including Spanish and Portuguese registries, led to the identification of >250 different mutations. It is a challenge to determine the pathogenic effect of potential splice site mutations on VWF mRNA. [...]
2019 - 10.3324/haematol.2018.203166
Haematologica, Vol. 104 (march 2019) , p. 587-598  

Dipòsit Digital de Documents de la UAB : 16 registres trobats   1 - 10següent  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.